Search

Your search keyword '"Licciardi, Paul"' showing total 557 results
Start Over Author "Licciardi, Paul"
557 results on '"Licciardi, Paul"'

3. Hearing loss in Australian First Nations children at 6-monthly assessments from age 12 to 36 months: Secondary outcomes from randomised controlled trials of novel pneumococcal conjugate vaccine schedules

Author

Leach, Amanda Jane, Wilson, Nicole, Arrowsmith, Beth, Beissbarth, Jemima, Mulholland, Kim, Santosham, Mathuram, Torzillo, Paul John, McIntyre, Peter, Smith-Vaughan, Heidi, Skull, Sue A., Oguoma, Victor M., Chatfield, Mark D., Lehmann, Deborah, Brennan-Jones, Christopher G., Binks, Michael J., Licciardi, Paul V., Andrews, Ross M., Snelling, Tom, Krause, Vicki, Carapetis, Jonathan, Chang, Anne B., and Morris, Peter Stanley

Subjects
Australian aborigines -- Health aspects, Infants -- Health aspects, Otitis media -- Complications and side effects, Hearing disorders in children -- Risk factors -- Statistics -- Demographic aspects, Pediatric research, Biological sciences
Abstract

Background In Australian remote communities, First Nations children with otitis media (OM)-related hearing loss are disproportionately at risk of developmental delay and poor school performance, compared to those with normal hearing. Our objective was to compare OM-related hearing loss in children randomised to one of 2 pneumococcal conjugate vaccine (PCV) formulations. Methods and findings In 2 sequential parallel, open-label, randomised controlled trials (the PREVIX trials), eligible infants were first allocated 1:1:1 at age 28 to 38 days to standard or mixed PCV schedules, then at age 12 months to PCV13 (13-valent pneumococcal conjugate vaccine, +P) or PHiD-CV10 (10-valent pneumococcal Haemophilus influenzae protein D conjugate vaccine, +S) (1:1). Here, we report prevalence and level of hearing loss outcomes in the +P and +S groups at 6-monthly scheduled assessments from age 12 to 36 months. From March 2013 to September 2018, 261 infants were enrolled and 461 hearing assessments were performed. Prevalence of hearing loss was 78% (25/32) in the +P group and 71% (20/28) in the +S group at baseline, declining to 52% (28/54) in the +P groups and 56% (33/59) in the +S group at age 36 months. At primary endpoint age 18 months, prevalence of moderate (disabling) hearing loss was 21% (9/42) in the +P group and 41% (20/49) in the +S group (difference -19%; (95% confidence interval (CI) [-38, -1], p = 0.07) and prevalence of no hearing loss was 36% (15/42) in the +P group and 16% (8/49) in the +S group (difference 19%; (95% CI [2, 37], p = 0.05). At subsequent time points, prevalence of moderate hearing loss remained lower in the +P group: differences -3%; (95% CI [-23, 18], p = 1.00 at age 24 months), -12%; (95% CI [-30, 6], p = 0.29 at age 30 months), and -9%; (95% CI [-23, 5], p = 0.25 at age 36 months). A major limitation was the small sample size, hence low power to reach statistical significance, thereby reducing confidence in the effect size. Conclusions In this study, we observed a high prevalence and persistence of moderate (disabling) hearing loss throughout early childhood. We found a lower prevalence of moderate hearing loss and correspondingly higher prevalence of no hearing loss in the +P group, which may have substantial benefits for high-risk children, their families, and society, but warrant further investigation. Trial registration ClinicalTrials.gov NCT01735084 and NCT01174849, Author(s): Amanda Jane Leach 1,*, Nicole Wilson 1, Beth Arrowsmith 1,2, Jemima Beissbarth 1, Kim Mulholland 3,4,5, Mathuram Santosham 6,7, Paul John Torzillo 8,9, Peter McIntyre 10,11, Heidi Smith-Vaughan 1, [...]

Published
2024
Full Text
View/download PDF

6. Differential anti-viral response to respiratory syncytial virus A in preterm and term infants

Author

Anderson, Jeremy, Imran, Samira, Ng, Yan Yung, Wang, Tongtong, Ashley, Sarah, Minh Thang, Cao, Quang Thanh, Le, Thi Trang Dai, Vo, Van Thanh, Phan, Thi Hong Nhu, Bui, Ngoc Xuan Trang, Do, Thi Phuong Trinh, Phan, Thanh Binh, Le, Thuong Vu, Nguyen, Trong Toan, Nguyen, Novakovic, Boris, Tang, Mimi L.K., Wurzel, Danielle, Mulholland, Kim, Pellicci, Daniel G., Do, Lien Anh Ha, and Licciardi, Paul V.

Published
2024
Full Text
View/download PDF

8. Immunogenicity, safety, and reactogenicity of a half- versus full-dose BNT162b2 (Pfizer-BioNTech) booster following a two-dose ChAdOx1 nCoV-19, BBIBP-CorV, or Gam-COVID-Vac priming schedule in Mongolia: a randomised, controlled, non-inferiority trial

Author

Batmunkh, Tsetsegsaikhan, Moore, Kerryn A., Thomson, Helen, Altangerel, Bolor, Amraa, Otgonjargal, Avaa, Naranbaatar, Batbayar, Lkhagvagaram, Batsukh, Khishigjargal, Bright, Kathryn, Burentogtokh, Tsogjargal, Ha Do, Lien Anh, Dorj, Gantuya, Hart, John D., Javkhlantugs, Khulan, Jigjidsuren, Sarantsetseg, Justice, Frances, Li, Shuo, Licciardi, Paul V., Mashbaatar, Khaliunaa, Mazarakis, Nadia, Neal, Eleanor F.G., Nguyen, Cattram Duong, Ochirbat, Batbayar, Tsolmon, Bilegtsaikhan, Tuya, Alimaa, Surenjav, Unursaikhan, von Mollendorf, Claire, and Mulholland, Kim

Published
2024
Full Text
View/download PDF

10. Efficacy against pneumococcal carriage and the immunogenicity of reduced-dose (0 + 1 and 1 + 1) PCV10 and PCV13 schedules in Ho Chi Minh City, Viet Nam: a parallel, single-blind, randomised controlled trial

Author

Balloch, Anne, Beissbarth, Jemima, Bright, Kathryn, Higgins, Rachel Ann, Hinds, Jason, Hoan, Pham Thi, Nation, Monica Larissa, Nguyen, Cattram Duong, Ortika, Belinda Daniela, Phan, Thanh V, Phuong, Tran Linh, Spry, Leena, Thuy, Ho Nguyen Loc, Toan, Nguyen Trong, Uyen, Doan Y, Vy, Le Thi Tuong, Temple, Beth, Tran, Hau Phuc, Dai, Vo Thi Trang, Smith-Vaughan, Heidi, Licciardi, Paul Vincent, Satzke, Catherine, Nguyen, Thuong Vu, and Mulholland, Kim

Published
2023
Full Text
View/download PDF

11. Memory B cell responses induced by pneumococcal conjugate vaccine schedules with fewer doses: analysis of a randomised-controlled trial in Viet Nam

Author

Ong, Darren, primary, Thanh, Phan Van, additional, Temple, Beth, additional, Toh, Zheng Quan, additional, Nguyen, Cattram, additional, Vientrung, Kien, additional, Nguyen, Hoang Van Anh, additional, Dai , Vo Thi Trang, additional, Bright, Kathryn, additional, Tran, Hau Phuc, additional, Higgins, Rachel, additional, Cheung, Yin Bun, additional, Nguyen, Thuong, additional, Mulholland, Kim, additional, and Licciardi, Paul, additional

Published
2024
Full Text
View/download PDF

13. Immunogenicity, otitis media, hearing impairment, and nasopharyngeal carriage 6-months after 13-valent or ten-valent booster pneumococcal conjugate vaccines, stratified by mixed priming schedules: PREVIX_COMBO and PREVIX_BOOST randomised controlled trials

Author

Leach, Amanda Jane, Wilson, Nicole, Arrowsmith, Beth, Beissbarth, Jemima, Mulholland, Edward Kim, Santosham, Mathuram, Torzillo, Paul John, McIntyre, Peter, Smith-Vaughan, Heidi, Chatfield, Mark D, Lehmann, Deborah, Binks, Michael, Chang, Anne B, Carapetis, Jonathan, Krause, Vicki, Andrews, Ross, Snelling, Tom, Skull, Sue A, Licciardi, Paul V, Oguoma, Victor M, and Morris, Peter Stanley

Published
2022
Full Text
View/download PDF

17. Sulforaphane prevents and reverses allergic airways disease in mice via anti-inflammatory, antioxidant, and epigenetic mechanisms

Author

Royce, Simon G., Licciardi, Paul V., Beh, Raymond C., Bourke, Jane E., Donovan, Chantal, Hung, Andrew, Khurana, Ishant, Liang, Julia J., Maxwell, Scott, Mazarakis, Nadia, Pitsillou, Eleni, Siow, Ya Yun, Snibson, Kenneth J., Tobin, Mark J., Ververis, Katherine, Vongsvivut, Jitraporn, Ziemann, Mark, Samuel, Chrishan S., Tang, Mimi L. K., El-Osta, Assam, and Karagiannis, Tom C.

Published
2022
Full Text
View/download PDF

19. WHO International Standards for antibodies to HPV6 HPV11 HPV31 HPV33 HPV45 HPV52 and HPV58.

Author

Kemp, Troy J., Panicker, Gitika, Eklund, Carina, Nie, Jianhui, Wang, Youchun, Beddows, Simon, Rigsby, Peter, Huang, Weijin, Dillner, Joakim, Unger, Elizabeth R., Pinto, Ligia A., Wilkinson, Dianna E., Licciardi, Paul, Toh, Zheng Quan, Müller, Martin, Rajanathan, T. M. Chozhavel, Li, Shaowei, Xia, Ningshao, Liu, Ge, and Zhou, Chenliang

Subjects
HUMAN papillomavirus, IMMUNE serums, STANDARDS, SEROLOGY, STANDARDIZATION
Abstract

Previously established World Health Organization (WHO) International Standards (IS) for anti-HPV16 and HPV18 antibodies are used to harmonize results across human papillomavirus (HPV) serology assays. Here, we present an international collaborative study to establish ISs for antibodies against HPV6 (NIBSC code 19/298), HPV11 (20/174), HPV31 (20/176), HPV33 (19/290), HPV45 (20/178), HPV52 (19/296) and HPV58 (19/300). The candidate standards were prepared using sera from naturally infected individuals. Each candidate was shown to be monospecific for reactivity against its indicated HPV type except for the HPV11 candidate, which was also reactive against other types. Expression of antibody levels relative to the relevant candidate IS reduced inter-laboratory variation allowing greater comparability between laboratories. Based on these results, the WHO Expert Committee on Biological Standardization established each of the 7 candidates as the 1st IS for antiserum to its indicated HPV type for use in the standardization of HPV pseudovirion-based neutralization and antibody-binding assays. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

20. Impaired IgM Memory B Cell Function Is Common in Coeliac Disease but Conjugate Pneumococcal Vaccination Induces Robust Protective Immunity

Author

Moscatelli, Olivia G., primary, Russell, Amy K., additional, Henneken, Lee M., additional, Hardy, Melinda Y., additional, Mazarakis, Nadia, additional, Higgins, Rachel, additional, Ekin, Jesse, additional, McLeod, Harry, additional, Simkin, Paul, additional, Licciardi, Paul V., additional, Bryant, Vanessa L., additional, and Tye-Din, Jason A., additional

Published
2024
Full Text
View/download PDF

21. Immunogenicity and impact on nasopharyngeal carriage of a single dose of PCV10 given to vietnamese children at 18 months of age

Author

Higgins, Rachel A, Temple, Beth, Dai, Vo Thi Trang, Phan, Thanh V, Toan, Nguyen Trong, Spry, Leena, Toh, Zheng Quan, Nation, Monica L, Ortika, Belinda D, Uyen, Doan Y, Cheung, Yin Bun, Nguyen, Cattram D, Bright, Kathryn, Hinds, Jason, Balloch, Anne, Smith-Vaughan, Heidi, Huu, Tran Ngoc, Mulholland, Kim, Satzke, Catherine, and Licciardi, Paul V

Published
2021
Full Text
View/download PDF

23. Interchangeability, immunogenicity and safety of a combined 10-valent pneumococcal Haemophilus influenzae protein D conjugate vaccine (Synflorix) and 13-valent-PCV (Prevenar13) schedule at 1-2-4-6 months: PREVIX_COMBO, a 3-arm randomised controlled trial

Author

Leach, Amanda Jane, Mulholland, Edward Kim, Santosham, Mathuram, Torzillo, Paul John, McIntyre, Peter, Smith-Vaughan, Heidi, Wilson, Nicole, Arrowsmith, Beth, Beissbarth, Jemima, Chatfield, Mark D., Oguoma, Victor M., Licciardi, Paul, Skull, Sue, Andrews, Ross, Carapetis, Jonathan, McDonnell, Joseph, Krause, Vicki, and Morris, Peter Stanley

Published
2021
Full Text
View/download PDF

24. Development of a human papillomavirus (HPV) multiplex immunoassay to profile HPV antibodies.

Author

Quang, Chau, Chung, Amy W., Kemp, Troy J., Ratu, Tupou, Tuivaga, Evelyn, Russell, Fiona M., Licciardi, Paul V., and Toh, Zheng Q.

Subjects
HUMAN papillomavirus, IMMUNOASSAY, IMMUNOGLOBULINS, FC receptors, ANTIBODY formation
Abstract

Neutralizing antibodies (NAbs) are considered the primary mechanism of vaccine‐mediated protection against human papillomaviruses (HPV), the causative agent of cervical cancer. However, the minimum level of NAb needed for protection is currently unknown. The HPV pseudovirion‐based neutralization assay (PBNA) is the gold standard method for assessing HPV antibody responses but is time‐consuming and labor‐intensive. With the development of higher valency HPV vaccines, alternative serological assays with the capacity for multiplexing would improve efficiency and output. Here we describe a multiplex bead‐based immunoassay to characterize the antibody responses to the seven oncogenic HPV types (HPV16/18/31/33/45/52/58) contained in the current licensed nonavalent HPV vaccine. This assay can measure antibody isotypes and subclasses (total IgG, IgM, IgA1–2, IgG1–4), and can be adapted to measure other antibody features (e.g., Fc receptors) that contribute to vaccine immunity. When tested with serum samples from unvaccinated and vaccinated individuals, we found high concordance between HPV‐specific IgG using this multiplex assay and NAbs measured with PBNA. Overall, this assay is high‐throughput, sample‐sparing, and time‐saving, providing an alternative to existing assays for the measurement and characterization of HPV antibody responses. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

26. Streptococcus pneumoniae serotype 33G: genetic, serological, and structural analysis of a new capsule type

Author

Manna, Sam, primary, Werren, Joel P., additional, Ortika, Belinda D., additional, Bellich, Barbara, additional, Pell, Casey L., additional, Nikolaou, Elissavet, additional, Gjuroski, Ilche, additional, Lo, Stephanie, additional, Hinds, Jason, additional, Tundev, Odgerel, additional, Dunne, Eileen M., additional, Gessner, Bradford D., additional, Bentley, Stephen D., additional, Russell, Fiona M., additional, Mulholland, E. Kim, additional, Mungun, Tuya, additional, von Mollendorf, Claire, additional, Licciardi, Paul V., additional, Cescutti, Paola, additional, Ravenscroft, Neil, additional, Hilty, Markus, additional, and Satzke, Catherine, additional

Published
2024
Full Text
View/download PDF

29. A case report describing the immune response of an infant with congenital heart disease and severe COVID-19

Author

Wurzel, Danielle, Neeland, Melanie R., Anderson, Jeremy, Abo, Yara-Natalie, Do, Lien Anh Ha, Donato, Celeste M., Bines, Julie E., Toh, Zheng Quan, Higgins, Rachel A., Jalali, Sedi, Cole, Theresa, Subbarao, Kanta, McMinn, Alissa, Dohle, Kate, Haeusler, Gabrielle M., McNab, Sarah, Alafaci, Annette, Overmars, Isabella, Clifford, Vanessa, Lee, Lai-yang, Daley, Andrew J., Buttery, Jim, Bryant, Penelope A., Burgner, David, Steer, Andrew, Tosif, Shidan, Konstantinov, Igor E., Duke, Trevor, Licciardi, Paul V., Pellicci, Daniel G., and Crawford, Nigel W.

Published
2021
Full Text
View/download PDF

30. Systems serology detects functionally distinct coronavirus antibody features in children and elderly

Author

Selva, Kevin J., van de Sandt, Carolien E., Lemke, Melissa M., Lee, Christina Y., Shoffner, Suzanne K., Chua, Brendon Y., Davis, Samantha K., Nguyen, Thi H. O., Rowntree, Louise C., Hensen, Luca, Koutsakos, Marios, Wong, Chinn Yi, Mordant, Francesca, Jackson, David C., Flanagan, Katie L., Crowe, Jane, Tosif, Shidan, Neeland, Melanie R., Sutton, Philip, Licciardi, Paul V., Crawford, Nigel W., Cheng, Allen C., Doolan, Denise L., Amanat, Fatima, Krammer, Florian, Chappell, Keith, Modhiran, Naphak, Watterson, Daniel, Young, Paul, Lee, Wen Shi, Wines, Bruce D., Mark Hogarth, P., Esterbauer, Robyn, Kelly, Hannah G., Tan, Hyon-Xhi, Juno, Jennifer A., Wheatley, Adam K., Kent, Stephen J., Arnold, Kelly B., Kedzierska, Katherine, and Chung, Amy W.

Published
2021
Full Text
View/download PDF

31. Persistence of SARS-CoV-2--Specific IgG in Children 6 Months After Infection, Australia

Author

Toh, Zheng Quan, Higgins, Rachel A., Do, Lien Anh Ha, Rautenbacher, Karin, Mordant, Francesca L., Subbarao, Kanta, Dohle, Kate, Nguyen, Jill, Steer, Andrew C., Tosif, Shidan, Crawford, Nigel W., Mulholland, Kim, and Licciardi, Paul V.

Subjects
Immune response -- Health aspects, Immunoglobulin G -- Health aspects, Pediatric research, Health
Abstract

The duration of the humoral immune response in children infected with severe acute respiratory syndrome coronavirus 2 is unknown. We detected specific IgG 6 months after infection in children who [...]

Published
2021
Full Text
View/download PDF

34. Immunogenicity and safety of BNT162b2 vaccination in adolescents with systemic lupus erythematosus.

Author

Piyaphanee, Nuntawan, Charuvanij, Sirirat, Thepveera, Sutheera, Toh, Zheng Quan, Licciardi, Paul V., Pattaragarn, Anirut, Wongprompitak, Patimaporn, Boonnak, Kobporn, Pheerapanyawaranun, Chatkamol, and Chokephaibulkit, Kulkanya

Subjects
SYSTEMIC lupus erythematosus, IMMUNE response, COVID-19 vaccines, VACCINE effectiveness, SARS-CoV-2 Omicron variant
Abstract

Objectives: We evaluated the immunogenicity and safety of BNT162b2 vaccination in adolescents with systemic lupus erythematosus (adoSLE) receiving either high- or low-dose immunosuppressant (High-IS and Low-IS). Methods: Patients aged 12–18 years diagnosed with SLE were enrolled. High-IS was defined as >7.5 mg/day prednisolone or with other immunosuppressant, while Low-IS was defined as only ≤7.5 mg/day of prednisolone and no immunosuppressant. Two doses of BNT162b2 vaccination were given 4 weeks apart, followed by a booster (third) dose at 4–6 months later. Anti-spike receptor binding domain (anti-RBD) IgG against Wuhan, neutralising antibody (NT) against Wuhan and Omicron variants, and cellular immune response by IFN-γ-ELISpot assay were evaluated following vaccination. Adverse events (AEs) and SLE flare were monitored. Results: A total of 73 participants were enrolled, 40 and 33 in the High-IS and Low-IS group, respectively. At 4 weeks following the 2nd dose, overall anti-RBD IgG seropositivity was 97.3%, with no difference between the groups (p =.498). AdoSLE on High-IS had lower anti-RBD IgG (p <.001), Wuhan NT (p <.001), and IFN-γ-ELISpot (p =.022) than those on Low-IS. A 3rd dose induced significantly higher antibody responses than after the 2nd dose (p <.001) in both groups and established seroconversion against Omicron variants, with persistent lower antibody levels in High-IS group. SELENA-SLEDAI scores within 12 weeks after 2-dose vaccination was higher than before vaccination (3.1 vs 2.5; p <.036); however, the occurrence of disease flare by SELENA-SLEDAI flare index was not different after vaccination compared to before vaccination, consistent across groups. Non-severe AEs occurred similarly in both groups. Conclusion: AdoSLE on High-IS induced lower SARS-CoV-2 vaccine immune responses than Low-IS. Vaccination can increase disease activity and requires close monitoring for disease flare. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

35. Streptococcus pneumoniae serotype 33G: genetic, serological, and structural analysis of a new capsule type

Author

Manna, Sam, primary, Werren, Joel P, additional, Ortika, Belinda D, additional, Bellich, Barbara, additional, Pell, Casey L, additional, Nikolaou, Elissavet, additional, Gjuroski, Ilche, additional, Lo, Stephanie W, additional, Hinds, Jason, additional, Tundev, Odgerel, additional, Dunne, Eileen M, additional, Gessner, Bradford D, additional, Bentley, Stephen D, additional, Russell, Fiona, additional, Mulholland, E. Kim, additional, Mungun, Tuya, additional, von Mollendorf, Claire, additional, Licciardi, Paul V, additional, Cescutti, Paola, additional, Ravenscroft, Neil, additional, Hilty, Markus, additional, and Satzke, Catherine, additional

Published
2023
Full Text
View/download PDF

36. Efficacy against pneumococcal carriage and the immunogenicity of reduced-dose (0 + 1 and 1 + 1) PCV10 and PCV13 schedules in Ho Chi Minh City, Viet Nam: a parallel, single-blind, randomised controlled trial

Author

Temple, Beth, primary, Tran, Hau Phuc, additional, Dai, Vo Thi Trang, additional, Smith-Vaughan, Heidi, additional, Licciardi, Paul Vincent, additional, Satzke, Catherine, additional, Nguyen, Thuong Vu, additional, Mulholland, Kim, additional, Balloch, Anne, additional, Beissbarth, Jemima, additional, Bright, Kathryn, additional, Higgins, Rachel Ann, additional, Hinds, Jason, additional, Hoan, Pham Thi, additional, Nation, Monica Larissa, additional, Nguyen, Cattram Duong, additional, Ortika, Belinda Daniela, additional, Phan, Thanh V, additional, Phuong, Tran Linh, additional, Spry, Leena, additional, Thuy, Ho Nguyen Loc, additional, Toan, Nguyen Trong, additional, Uyen, Doan Y, additional, and Vy, Le Thi Tuong, additional

Published
2023
Full Text
View/download PDF

37. Randomised controlled trial of perinatal vitamin D supplementation to prevent early-onset acute respiratory infections among Australian First Nations children: the ‘D-Kids’ study protocol

Author

Binks, Michael J, primary, Bleakley, Amy S, additional, Pizzutto, Susan J, additional, Lamberth, Michelle, additional, Powell, Verity, additional, Nelson, Jane, additional, Kirby, Adrienne, additional, Morris, Peter S, additional, Simon, David, additional, Mulholland, E Kim, additional, Rathnayake, Geetha, additional, Leach, Amanda J, additional, D'Antoine, Heather, additional, Licciardi, Paul V, additional, Snelling, Tom, additional, and Chang, Anne B, additional

Published
2023
Full Text
View/download PDF

41. Immune responses to SARS-CoV-2 in three children of parents with symptomatic COVID-19

Author

Tosif, Shidan, Neeland, Melanie R., Sutton, Philip, Licciardi, Paul V., Sarkar, Sohinee, Selva, Kevin J., Do, Lien Anh Ha, Donato, Celeste, Quan Toh, Zheng, Higgins, Rachel, Van de Sandt, Carolien, Lemke, Melissa M., Lee, Christina Y., Shoffner, Suzanne K., Flanagan, Katie L., Arnold, Kelly B., Mordant, Francesca L., Mulholland, Kim, Bines, Julie, Dohle, Kate, Pellicci, Daniel G., Curtis, Nigel, McNab, Sarah, Steer, Andrew, Saffery, Richard, Subbarao, Kanta, Chung, Amy W., Kedzierska, Katherine, Burgner, David P., and Crawford, Nigel W.

Published
2020
Full Text
View/download PDF

42. Sustained Antibody Responses 6 Years Following 1, 2, or 3 Doses of Quadrivalent Human Papillomavirus (HPV) Vaccine in Adolescent Fijian Girls, and Subsequent Responses to a Single Dose of Bivalent HPV Vaccine: A Prospective Cohort Study

Author

Toh, Zheng Quan, Russell, Fiona M., Reyburn, Rita, Fong, James, Tuivaga, Evelyn, Ratu, Tupou, Nguyen, Cattram D., Devi, Rachel, Kama, Mike, Matanitobua, Silivia, Tabrizi, Sepehr N., Garland, Suzanne M., Sinha, Rohit, Frazer, Ian, Tikoduadua, Lisi, Kado, Joseph, Rafai, Eric, Mulholland, Edward K., and Licciardi, Paul V.

Published
2017

44. Immunogenicity and Reactogenicity of Messenger RNA Coronavirus Disease 2019 Vaccine Booster Administered by Intradermal or Intramuscular Route in Thai Older Adults

Author

Assantachai, Prasert, primary, Niyomnaitham, Suvimol, additional, Chatthanawaree, Wichai, additional, Intalapaporn, Somboon, additional, Muangpaisan, Weerasak, additional, Phannarus, Harisd, additional, Saichompoo, Rangsimatiti Binda, additional, Sura-amonrattana, Unchana, additional, Wongprompitak, Patimaporn, additional, Toh, Zheng Quan, additional, Licciardi, Paul V, additional, Srisutthisamphan, Kanjana, additional, and Chokephaibulkit, Kulkanya, additional

Published
2023
Full Text
View/download PDF

46. Immunogenicity and reactogenicity of repeated intradermal mRNA COVID-19 vaccines administered as a second booster dose in a Thai geriatric population.

Author

Prasert Assantachai, Suvimol Niyomnaitham, Zheng Quan Toh, Monthira Thammasalee, Napaporn Pengsorn, Wiyachatr Monklang, Licciardi, Paul V., and Kulkanya Chokephaibulkit

Subjects
BOOSTER vaccines, THAI people, COVID-19 vaccines, IMMUNE response, VACCINE effectiveness
Abstract

Background: Geriatric populations are at an increased risk of severe presentations, hospitalization, and loss of life from COVID-19. Few studies have explored vaccination regimens in adults >65 years old. Repeated booster vaccination is required for high-risk populations as COVID-19 vaccine efficacy is short-lived. We compared the immunogenicity and reactogenicity of second intradermal (ID) COVID-19 booster vaccination with second intramuscular (IM) vaccination in older adults. Methods: This single-center, open-labeled, prospective, cohort study conducted at Siriraj Hospital enrolled older adults =65 years old who previously received a first booster (third dose) mRNA vaccine (mRNA-1273 or BNT162b2) via ID or IM administration. Participants were allocated to receive a second booster of the same vaccine type and route as their first booster 16-17 weeks thereafter. Anti-SARS-CoV-2 receptor binding domain IgG and neutralizing antibody titers against Wuhan and Omicron subvariants (BA.1, BA.2, and BA.4/5) were measured 2 weeks after vaccination. Results: Of 91 enrolled participants, 72.5% were women, with a median age of 75 years. Forty-nine participants (53.8%) received a second ID booster, and 42 (46.2%) received a second IM booster. Two weeks after the second booster, all groups generated anamnestic IgG antibody responses that were 5.41- to 10.00-fold higher than at baseline. Overall, higher antibody GMTs against Wuhan and Omicron subvariants were observed in IM compared with ID regimens. ID mRNA-1273 induced similar GMTs to IM BNT162b2 2 weeks after the second booster against Wuhan (486.77 [321.48, 737.05] vs. 472.63 [291.24, 767.01], respectively; p = 0.072). Higher GMTs against Omicron BA.1 (GMR [95% CI], 1.71 [1.39, 2.11]; p = 0.023), BA.2 (1.34 [1.11, 1.62]; p = 0.845), and BA.4/5 (1.10 [0.92, 1.33]; p = 0.531) were seen in all groups at 2 weeks after the second booster compared with 2-4 weeks after the first booster. Both local and systemic AEs were less frequent after the second than after the first booster, regardless of administrative route and vaccine type. Local AEs were significantly more frequent in ID mRNA-1273 arms than their respective BNT162b2 arms 2 weeks after the second booster (ID-mRNA-1273 vs. ID-BNT162b2: p = 0.001). Conclusion: Repeated fractional ID vaccination may be an alternative booster vaccination strategy for geriatric populations. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

47. TLR Responses in Preterm and Term Infant Cord Blood Mononuclear Cells

Author

Anderson, Jeremy, primary, Bender, Georgia, additional, Minh Thang, Cao, additional, Quang Thanh, Le, additional, Thi Trang Dai, Vo, additional, Van Thanh, Phan, additional, Thi Hong Nhu, Bui, additional, Ngoc Xuan Trang, Do, additional, Thi Phuong Trinh, Phan, additional, Vu Thuong, Nguyen, additional, Trong Toan, Nguyen, additional, Mulholland, Kim, additional, Pellicci, Daniel G., additional, Anh Ha Do, Lien, additional, and Licciardi, Paul V., additional

Published
2023
Full Text
View/download PDF

48. Therapeutic immunization with a whole cell vaccine reduces pneumococcal nasopharyngeal density, shedding, and middle ear infection in mice

Author

Manning, Jayne, primary, Manna, Sam, additional, Dunne, Eileen M, additional, Bongcaron, Viktoria, additional, Pell, Casey, additional, Patterson, Natalie L, additional, Kuil, Sacha D, additional, Dhar, Poshmaal, additional, Goldblatt, David, additional, Mulholland, E Kim, additional, Licciardi, Paul V, additional, Robins-Browne, Roy M, additional, Malley, Richard, additional, Wijburg, Odilia, additional, and Satzke, Catherine, additional

Published
2023
Full Text
View/download PDF

49. The Interleukin-11/IL-11 Receptor Promotes Glioblastoma Survival and Invasion under Glucose-Starved Conditions through Enhanced Glutaminolysis

Author

Stuart, Sarah F., primary, Bezawork-Geleta, Ayenachew, additional, Areeb, Zammam, additional, Gomez, Juliana, additional, Tsui, Vanessa, additional, Zulkifli, Ahmad, additional, Paradiso, Lucia, additional, Jones, Jordan, additional, Nguyen, Hong P. T., additional, Putoczki, Tracy L., additional, Licciardi, Paul V., additional, Kannourakis, George, additional, Morokoff, Andrew P., additional, Achuthan, Adrian A., additional, and Luwor, Rodney B., additional

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results